The ph 2 data showed a statistically significant benefit of bapineuzumab over PBO in the ApoE4 non-carrier population on almost every measure. The caveats are that this was a post-hoc analysis and the PBO decline was a little worse than historical average.
In the same post-hoc, bapineuzumab did not show benefit over PBO on ANY measure in the carrier population
Part of the retrospective rationale is that maybe the carrier population has a more aggressive disease and needs to be treated earlier.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.